AnDiCon Bio raises $15.7M in Series Pre-A to develop COVID pill; LevoStar, Junshi, Huadong
Elise Mak · 04/11/2022
Jiaxing-based biotech startup AnDiCon Bio has raised RMB100 million to help it develop an oral drug for COVID that is s improved based on Pfizer's nirmatrelvir. More news from LevoStar, Junshi, Huadong and the CDE.
China’s CDE offers assistance and encourages communication for breakthrough therapy reviews
Minhua Chu · 03/28/2022
China’s CDE has told drugmakers to communicate more with them and will offer guidance for breakthrough therapy applications.
MediLink Therapeutics nabs $70M to develop ADCs; Nutshell Therapeutics, Yuesai Bio, Hansoh Pharma - News of the day
Elise Mak · 03/14/2022
Suzhou biotech MediLink Therapeutics has closed a $70 million Series B round to support the clinical development of new-generation ADCs. More news from Nutshell Therapeutics, Yuesai Bio, Hansoh Pharma, Sobi, CStone, the NMPA and the CDE.
China’s CDE issues new guidelines for COVID-19 drug trials
Minhua Chu · 02/28/2022
The CDE issued a new batch of guidelines that covers the subjects, primary endpoints and design of clinical trials for COVID-19 drugs. The move came six days after the NMPA granted conditional approval for Pfizer's Paxlovid.
Hualan Biological Bacterin launches $400M IPO in Shenzhen; Kexing, Starmab, Jigene - News of the day
Elise Mak · 02/21/2022
Vaccine developer Hualan Biological Bacterin raised RMB 2.28 billion ($400 million) on the ChiNext market on the Shenzhen Stock Exchange on Feb. 18. More news from Kexing, Starmab, Jigene, Haihe Pharma, Carsgen Therapeutics, Immune-Onc Therapeutics, Dizal Pharmaceutical, CDE and NHC.
Innovent's hypercholesterolemia studies of PCSK-9 inhibitor met primary endpoint; RemeGen, CDE - News of the day
Elise Mak · 02/18/2022
Innovent Biologics said its IBI306, a recombinant full-human anti-PCSK-9 monoclonal antibody, met primary endpoint in two Chinese registration studies in non-familiar hypercholesterolemia (non-FH) patients at high or very high cardiovascular risk as well as in patients with hypercholesterolemia. More news from RemeGen and the CDE.
Clover's vaccine 67% effective against COVID-19, booster trial ongoing; Gloria, ETERN, Iregene - News of the day
Elise Mak · 01/24/2022
Clover Biopharmaceuticals is conducting trials to evaluate its COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum), as a universal COVID-19 booster vaccine.
Leap's DKK1 antibody plus BeiGene's PD-1 drug show promise for gastric cancer; Eluminex Bio, CTTQ, Neurophth - News of the day
Elise Mak · 01/21/2022
Leap Therapeutics' anti-DKK1 antibody in combination with BeiGene's anti-PD-1 antibody demonstrated clinical activity in both first- and second-line advanced gastric or gastroesophageal junction cancer patients. More news from Eluminex Bio, CTTQ, Neurophth, BeiGene and the CDE.
New cell therapy startup Binhu Biotech raises nearly $31.3M; Xellsmart, Youcare, BeiGene - News of the day
Elise Mak · 01/11/2022
Incubated by Legend Capital, Binhu Biotech said it has raised nearly RMB200 million to develop universal cell and gene therapies for oncology, autoimmune diseases, and genetic diseases, and more news from Xellsmart, Youcare, BeiGene, CANbridge, Eli Lilly, JW Therapeutics and Chinese regulators.
Copyright © 2016-2022 PharmaDJ .All Rights Reserved.   Suggestions and feedback:   Record/License No.:沪ICP备17054709号-1  
About PharmaDJ | Subscription | Contact Us | Copyright Statement